Anti-tumour activity of a first-in-class agent NUC-1031 in patients with advanced cancer: results of a phase I study

Pharmacological factors affecting accumulation of gemcitabine’s active metabolite, gemcitabine triphosphate

(2017) Ivana Rizzuto et al.   PHARMACOGENOMICS

A first-in-human phase I and pharmacokinetic study of CP-4126 (CO-101), a nucleoside analogue, in patients with advanced solid tumours

(2015) B. Venugopal et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Phase I dose escalation and pharmacokinetic evaluation of two different schedules of LY2334737, an oral gemcitabine prodrug, in patients with advanced solid tumors

(2015) Sandrine J. Faivre et al.   INVESTIGATIONAL NEW DRUGS

Gemcitabine: Metabolism and molecular mechanisms of action, sensitivity and chemoresistance in pancreatic cancer

(2014) Lucas de Sousa Cavalcante et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Application of ProTide Technology to Gemcitabine: A Successful Approach to Overcome the Key Cancer Resistance Mechanisms Leads to a New Agent (NUC-1031) in Clinical Development

(2014) Magdalena Slusarczyk et al.   JOURNAL OF MEDICINAL CHEMISTRY

Randomized, Multicenter, Phase II Study of CO-101 Versus Gemcitabine in Patients With Metastatic Pancreatic Ductal Adenocarcinoma: Including a Prospective Evaluation of the Role of hENT1 in Gemcitabine or CO-101 Sensitivity

(2013) Elizabeth Poplin et al.   JOURNAL OF CLINICAL ONCOLOGY

Harnessing gemcitabine metabolism: a step towards personalized medicine for pancreatic cancer

(2012) Muhammad Wasif Saif et al.   Therapeutic Advances in Medical Oncology

FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer

(2011) Thierry Conroy et al.   NEW ENGLAND JOURNAL OF MEDICINE

Gemcitabine Resistance in Pancreatic Cancer: Picking the Key Players

(2008) M. P. Kim et al.   CLINICAL CANCER RESEARCH

Prolonged Versus Standard Gemcitabine Infusion: Translation of Molecular Pharmacology to New Treatment Strategy

(2008) S. A. Veltkamp et al.   ONCOLOGIST